Ton Lisman Selected Research

Factor VIII (Coagulation Factor VIII)

5/2022	Acquired bleeding disorders.
10/2021	Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.
2/2021	Acquired bleeding disorders.
1/2021	Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.
1/2020	Author response to Letter to the Editor: 'AB0, von Willebrand factor/Factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?'
1/2020	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.
6/2010	Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ton Lisman Research Topics

Disease

48	Hemorrhage 01/2022 - 03/2002
45	Fibrosis (Cirrhosis) 07/2022 - 03/2002
42	Liver Diseases (Liver Disease) 09/2022 - 07/2006
33	Thrombosis (Thrombus) 01/2022 - 03/2006
9	Thrombophilia 01/2022 - 02/2005
8	COVID-19 10/2021 - 10/2020
8	Thrombocytopenia (Thrombopenia) 01/2021 - 02/2008
7	Inflammation (Inflammations) 07/2022 - 07/2009
7	Acute Liver Failure (Fulminant Hepatic Failure) 07/2022 - 06/2010
7	Venous Thrombosis (Deep-Vein Thrombosis) 10/2021 - 05/2007
7	End Stage Liver Disease 09/2020 - 01/2007
6	Acute-On-Chronic Liver Failure 07/2022 - 09/2020
5	Hemophilia A (Haemophilia) 05/2022 - 01/2002
5	Liver Cirrhosis (Hepatic Cirrhosis) 01/2017 - 03/2007
5	Pathologic Constriction (Stenosis) 01/2015 - 08/2011
4	Hepatic Encephalopathy 03/2022 - 04/2016
4	Portal Hypertension 01/2022 - 01/2007
4	Myocardial Infarction 10/2021 - 06/2009
4	Reperfusion Injury 09/2021 - 08/2012
4	Ischemia 01/2019 - 08/2011
4	Non-alcoholic Fatty Liver Disease 02/2017 - 01/2015
3	Neoplasms (Cancer) 01/2022 - 09/2004
3	Disease Progression 01/2022 - 01/2015
3	Critical Illness (Critically Ill) 01/2022 - 01/2021
3	Disease Susceptibility (Diathesis) 01/2014 - 03/2002
3	Thrombasthenia (Glanzmann Thrombasthenia) 04/2008 - 03/2003
2	Pulmonary Embolism 10/2021 - 08/2004
2	Wounds and Injuries (Trauma) 10/2021 - 03/2017
2	Sepsis (Septicemia) 01/2021 - 06/2010
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 11/2007
2	Disseminated Intravascular Coagulation 01/2019 - 03/2017
2	von Willebrand Diseases (von Willebrand's Disease) 01/2018 - 03/2007
2	Liver Failure 03/2017 - 08/2010
2	Obesity 11/2016 - 06/2016
2	Fatty Liver 11/2016 - 09/2015
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/2016 - 07/2009
2	Hepatitis B 02/2015 - 01/2015
2	Hepatitis 01/2015 - 03/2010
2	Sclerosing Cholangitis 04/2014 - 09/2011
1	Leg Injuries (Leg Injury) 01/2022
1	Brain Death (Brain Dead) 01/2022
1	Ascites 01/2022
1	Virus Diseases (Viral Diseases) 10/2021

Drug/Important Bio-Agent (IBA)

53	Hemostatics (Antihemorrhagics)IBA 07/2022 - 07/2006
32	AnticoagulantsIBA 07/2022 - 03/2006
23	Thrombin FDA Link 09/2022 - 04/2008
19	von Willebrand FactorIBA 07/2022 - 07/2006
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2006
12	Heparin (Liquaemin)FDA LinkGeneric 10/2021 - 08/2004
9	recombinant FVIIa (rFVIIa)FDA Link 11/2020 - 01/2002
8	Fibrinogen (Factor I)FDA Link 01/2022 - 06/2016
8	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2021 - 08/2004
7	Factor VIII (Coagulation Factor VIII)IBA 05/2022 - 06/2010
7	FibrinIBA 01/2022 - 05/2007
6	fibrin fragment D (D-dimer)IBA 01/2022 - 01/2017
6	ThrombomodulinIBA 01/2022 - 08/2005
6	Blood Coagulation Factors (Coagulation Factor)IBA 01/2022 - 07/2008
6	AntigensIBA 01/2021 - 07/2006
6	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 03/2017 - 01/2002
6	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2017 - 08/2005
5	Thromboplastin (Tissue Factor)IBA 07/2022 - 09/2004
5	Antifibrinolytic Agents (Antifibrinolytics)IBA 07/2021 - 06/2008
5	PlasminogenIBA 03/2017 - 05/2007
5	nasIBA 01/2015 - 08/2011
4	Prothrombin (Factor II)IBA 01/2022 - 07/2013
4	Pharmaceutical PreparationsIBA 01/2014 - 01/2002
3	Oral ContraceptivesIBA 01/2022 - 05/2008
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 09/2004
3	Vitamin K FDA Link 01/2022 - 01/2019
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 09/2019
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2019
3	Plasminogen Activator Inhibitor 1IBA 10/2021 - 07/2009
3	AntithrombinsIBA 01/2021 - 12/2013
3	Fibrinolysin FDA Link 01/2021 - 01/2015
3	Plasminogen Activators (Plasminogen Activator)IBA 01/2017 - 05/2007
3	CollagenIBA 06/2010 - 07/2006
2	AutoantibodiesIBA 05/2022 - 02/2021
2	Cell-Free Nucleic AcidsIBA 01/2022 - 09/2019
2	Thiobarbituric Acid Reactive SubstancesIBA 01/2022 - 09/2019
2	dicarboxydine (DCD)IBA 01/2022 - 10/2015
2	ThrombospondinsIBA 01/2021 - 01/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 01/2015
2	RivaroxabanIBA 04/2015 - 01/2014
2	Fondaparinux (Arixtra)FDA Link 01/2014 - 12/2013
2	factor V LeidenIBA 09/2011 - 05/2008
2	AntibodiesIBA 02/2008 - 01/2002
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	LipopolysaccharidesIBA 01/2022
1	Tranexamic Acid (AMCA)FDA Link 10/2021
1	Angiotensin-Converting Enzyme 2IBA 10/2021

Therapy/Procedure

34	Liver Transplantation 01/2022 - 03/2002
14	Therapeutics 01/2022 - 07/2013
8	Transplantation 01/2022 - 08/2013
5	Hepatectomy 12/2017 - 01/2015
3	Kidney Transplantation 12/2021 - 01/2018
3	Platelet Transfusion (Blood Platelet Transfusions) 01/2021 - 07/2008
2	Critical Care (Surgical Intensive Care) 03/2022 - 07/2019
2	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2021 - 04/2016
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 01/2022
1	Contraindications 11/2021